This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
spk06: Good day and welcome to the G1 Therapeutics fourth quarter financial results conference call. At this time, all participants are in a listen-only mode. After the speaker presentation, there will be a question and answer session. To ask a question during the session, you will need to press star 1 1 on your telephone. You will then hear an automated message advising that your hand has been raised. To withdraw your question, please press star 1 1 again. Please be advised that today's conference is being recorded. It is now my pleasure to introduce Vice President of Communications, Will Roberts.
spk03: Thank you, Andrew. Good morning, everyone, and welcome to the G1 Conference call to discuss our fourth quarter and full year 2022 financial results and business update. The press release on these financial results was issued this morning and can be found in the news section of our corporate website, g1therapeutics.com. On this morning's call, the team will provide a business overview of the fourth quarter of 2022, including an update on our clinical programs and our commercial progress in that period with COSELLA, which is approved and commercially available to decrease the incidence of chemotherapy-induced myelosuppression in adult patients who had administered prior to a platinum atoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer. A Q&A session will follow the prepared remarks. Before we begin, I'd like to remind you that today's webcast contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements represent management's judgment as of today and may involve risk and uncertainty that could cause actual results to differ materially from those expressed in or implied by these statements. For more information on such risk and uncertainties, please refer to our filings with the Securities and Exchange Commission, which are available from the SEC or on our corporate website. Any forward-looking statements represent our views as of today, March 1st, 2023. Joining me on the call today are Jack Bailey, our Chief Executive Officer, Raj Malek, our Chief Medical Officer, Andrew Perry, our Chief Commercial Officer, and Jen Moses, our Chief Financial Officer. And with that, I'll turn the call over to Jack.
spk00: Thanks, Will. Good morning, everyone, and thank you for joining us on the call today. We spoke with you just a couple of weeks ago on the PreserveOne results. Since that time, we continue to move forward with urgency on the rest of the business, focusing on three core goals. First, regarding sales and small cell lung cancer, we remain confident in the sales trajectory for Cosella in our first lung cancer indication. As you will hear from Andrew, our sales and marketing teams have executed well since the start of the fourth quarter of 2022, and bio volume growth returned after experiencing a flat third quarter. This has continued into the first quarter of 2023 with a record month of sales in January and our highest week ever of sales in February. Based on what we are seeing today, we expect our 2023 net co-seller sales to be in the range of $50 to $60 million, an increase of up to 92% over 2022. Second, as Raj will describe, we are focused on executing on our ongoing clinical trials to achieve near-term data readouts. In particular, our ADC and MOA phase twos and our phase three in triple negative breast cancer. Regarding the two phase twos, initial data were compelling. We observed clinically meaningful on-target effects of trilocyclic to reduce the rates of multiple adverse events when administered prior to the ADC thocituzumab, including myelosuppression and diarrhea. And the initial results from our mechanism of action trial in neoadjuvant TMBC showed favorable alterations in the tumor microenvironment from just a single dose of trilocyclic monotherapy. And third, we have moved quickly to make the necessary organizational changes to preserve capital, including reducing the workforce by nearly 30%, though the sales team remains intact. and also other prudent decisions to reduce spend and extend our cash runway through each of our clinical readouts, including the TMBC pivotal trial. Jen will provide more color on these topics. We will take these three goals in order. Andrew will first cover our recent commercial efforts since the start of the fourth quarter of 2022. Raj will then provide an update on our clinical program, including a brief overview of the results of PreserveOne and our efforts to understand those results. Finally, Jen will provide financial results for the quarter and, as mentioned, discuss the actions we have taken to extend our cash runway. Then I'll be back for some concluding comments. With that, I'll turn the call over to Andrew. Thank you, Jack.
spk05: I'm glad to be with you today to provide an update on our fourth quarter 2022 sales performance, the actions we took to drive growth in the fourth quarter, and how those actions have continued to deliver growth into Q1 2023. Our goals in the fourth quarter were to restore volume growth after a flat third quarter and to build a broader platform for future growth based on more customer organizations driving significant volume each quarter. We delivered on both of those goals in Q4, and I will discuss some of the factors underlying our performance today. Beginning with sales results, we ended the quarter with $8.9 million in net sales of Cosella, representing 8% file volume growth compared with Q3. Volume growth compared with fourth quarter in 2021 was 103%, demonstrating the continued progress we have made with sales execution. Volumes grew month over month throughout Q4 and have continued to grow in January and February 2023. In fact, January was our highest volume month launched to date, with volume strength continuing throughout February. Two months into Q1, our quarterly growth is tracking well above the 8% growth we are reporting today for Q4. As we stated on our last call, in the extensive-stage small-cell lung cancer market, our quarterly growth is highly reliant on gaining new patients either from new accounts or from existing accounts in order to compensate for patients who complete their chemotherapy regimen and drop-off therapy. I'm happy to report that we significantly increased the number of new accounts ordering Costella in Q4. We brought on board almost 100 new accounts in Q4 compared with around 70 in Q3. Moving into 2023, we have continued to add new accounts at the rate of around one per day. Many of these new accounts are affiliated with larger parent organizations, and we added eight new top 100 organizations in Q4, and two so far in Q1, giving us a total of 71 of the top 100 which have ordered Cosella launch to date. The most recent of these from just last week was one of the largest academic centers in the U.S., and demonstrates the continued interest in the unique benefits of CoSella. Within Q4, 54 of those organizations had orders, which supports our continued high overall reorder rate of around 80%. Our estimate of CoSella patient share continues to grow, and in Q4 increased to approximately 9% in the first-line market, which represents the majority of our use. One of our goals as we grow our business is to create a broader platform of organizations with deep adoptions, For most quarters since launch, three customer organizations have driven around 20% of volume in each quarter. In Q4, we saw five organizations driving 20% of volume. In fact, the highest volume organization in the fourth quarter grew over 400% from Q3 to Q4. In a relatively rare tumor type, such as small cell lung cancer, having more customers with deep adoption should provide more stability in our quarterly volumes. We saw 77% of volume in the quarter come through community clinics and hospitals and 23% of volume from academic centers. This reflects some of the high growth we saw in the quarter from large community clinic networks. 98% of our volume in the quarter was in commercial supply with 2% provided through our patient assistance program. Our payer mix remains stable with the majority covered by Medicare and third-party payer reimbursement has remained strong. Looking into Q1 2023, with several new top 100 organizations and many new accounts added in the prior quarter, we entered Q1 in a better position than the last quarter and have been encouraged by January and February demand. Our focus going forward is continuing to build a broader base of deeply adulting customers with emphasis on community clinic networks. We now have three volume-based agreements with large community oncology provider networks and are progressing additional contract opportunities. While these contracts can take a little time to fully get up to speed, we have already seen Q1 quarter to date increases in demand in these contracted organizations of over 30% so far. We have also continued to make operational efficiencies where it made sense, including some consolidation of territories and a redeployment of one sales representative to a virtual hybrid role that can augment our digital marketing and provide support for un-staffed territories. This was a quarter where we focused our execution on building a broader base of customers with high growth potential and were able to create sustained volume growth while also driving some efficiencies in our commercial model. Our performance in Q4 2022 and midway into Q1 2023 confirms that there remains significant growth potential in Small Cell for Cosella.
spk04: With that, I'll turn the call over to Raj. Thanks, Andrew, and good morning, everyone. As Jack mentioned, we've had a number of important data readouts since the end of the third quarter, although the most important of them, the Phase 3 readout from the Pivotal Preserve 1 trial, did not work out as we had hoped. I'll touch on each of them, starting with colorectal cancer, though I won't go into the same level of detail as I did on the call two weeks ago. Although the results were confounded by less favorable preliminary antitumor efficacy results, including early indicators of survival, PRESERVE-1 yet again confirmed the myeloprotection benefit of Trelacyclib. For example, the inclusion of Trelacyclib to Folfoxiri and Bevacizumab reduced the rates of many measures of myelosuppression compared to placebo, including achieving the co-primary endpoints with statistical significance. However, we decided to discontinue the trial given the low likelihood of achieving the PFS and OS endpoints based on the preliminary anti-tumor efficacy data to date. This adverse effect on anti-tumor efficacy appears to be limited to this chemotherapy regimen used in colorectal cancer, as other clinical trials of trilocyclic in combination with different chemotherapies in patients with extensive stage small cell lung cancer and triple negative breast cancer did not demonstrate this adverse anti-tumor efficacy signal. In fact, In the Phase II triple negative breast cancer study, we saw the opposite, a statistically significant improvement in overall survival in patients receiving trilocyclic compared to placebo. We are conducting a variety of analyses to understand the results. For example, we're looking into the possibility that trilocyclic may have had an unanticipated negative interaction with 5-FU, which would not have been identified as a risk in any of the preclinical assessments we performed. we looked to communicate the results of these and other analyses over the coming few months. Since the start of the fourth quarter, we also had readouts from each of our ongoing phase two trials. Starting with the ADC trial in combination with sasituzumab, initial results on the first 18 patients showed a clinically meaningful on-target effect of trilocycline to reduce the rates of multiple adverse events compared to sasituzumab single-agent data from the ASCEND trial, including any grade and grade 3-4 neutropenia, and any grade and grade 3-4 diarrhea. We expect to complete enrollment in this trial this week. We expect to present a more comprehensive data set, including safety and initial efficacy results, including outcome by tumor PD-L1 status, at a medical meeting in the second quarter of this year. In December, we presented initial results from our mechanism of action trial in neoadjuvant triple negative breast cancer at the San Antonio Breast Cancer Symposium. We noted favorable alterations in the tumor microenvironment following a single dose of tricyclic monotherapy, with a trend towards an increased CD8 T cell to T regulatory cell ratio, which is consistent with prior data. We expect to present initial tumor pathological complete response results, again including outcome by tumor PD-L1 status, in the second quarter of this year. And in January, we provided an initial update on Preserve 3 in bladder cancer, showing similar but numerically lower response rate in the trilocytobon. We anticipate additional safety and efficacy data, including preliminary progression-free survival data, in the middle of this year. Finally, our Phase III trial in triple negative breast cancer is based on the foundational data from our Phase II trial that showed a statistically significant survival advantage for patients enrolled in both tricyclic arms compared to placebo. We have previously said that the interim overall survival analysis was expected in the second half of 2023, following occurrence of 70% of the events required for the final analysis. Since the interim analysis is dependent on having the protocol-defined number of events, we track the occurrence of events in a blinded way at a regular interval. Based on recent evaluations, the number of actual events appear to be occurring more slowly than predicted. Therefore, we now expect the interim OS analysis to be conducted in the first half of 2024. As events accumulate, we'll be able to refine this estimate further. So a lot of data coming over the next several months. With that, I'll turn the call over to Jen for a review of the financial results. Jen?
spk02: Thanks, Raj, and good morning, everyone. As Will mentioned, full financial results for the fourth quarter and full year 2022 are available in this morning's press release and will be in the 10-K, which we intend to file today after market close. Our total revenue for the fourth quarter of 2022 was $10.3 million, comprised of net co-seller revenue of $8.9 million and license revenue of $1.4 million. The license revenue from the current quarter is primarily related to clinical trial reimbursements from our partners at Sincere and EQRX. For the same period in 2021, total revenue was $5.7 million, including $4.4 million of net product revenue. For the full year of 2022, total revenue was $51.3 million, comprised of $31.3 million in net co-seller revenue and AND LICENSED REVENUE OF $20 MILLION. COST OF GOODS SOLD FOR THE THREE MONTHS ENDED DECEMBER 31, 2022 WAS $1 MILLION, COMPARED TO $.4 MILLION FOR THE SAME PERIOD IN 2021. COST OF GOODS SOLD FOR THE FULL YEAR OF 2022 WAS $3.7 MILLION, COMPARED TO $2 MILLION FOR THE PRIOR YEAR. OUR RESEARCH AND DEVELOPMENT EXPENSES FOR THE FOURTH QUARTER OF 2022 WERE $16.6 MILLION, COMPARED TO $19.8 MILLION FOR THE FOURTH QUARTER OF 2021. The period-over-period decrease in R&D expenses was primarily due to reduced clinical trial costs. R&D expenses for the full year 2022 were $83.3 million compared to $76.2 million for the prior year. Our selling, general, and administrative expenses for the fourth quarter of 2022 were $23.6 million, relatively flat with the $23.2 million for the fourth quarter of 2021. Comparing the two periods, increases in personnel costs due to increased headcount and sales were offset by a decrease in fees paid to BI and decreased professional and administrative expenses. SG&A for the full year 2022 was $100.4 million compared to $95.7 million for 2021. Regarding our cash position, we ended 2022 with cash, cash equivalents, and liquid securities of $145.1 million compared to $221.2 million as of December 31st, 2021. This includes $52 million in net proceeds from our fourth quarter 2022 underwritten public offering. Finally, regarding revenue, expense, and cash runway guidance for 2023, As Jack mentioned, our net product revenue guidance for 2023 is a range between 50 and 60 million. This guidance reflects an adjustment to our anticipated gross to net percentage. Our gross to net adjustment in 2022 was in the mid to high teens. Going forward, we expect it to be in the low to mid 20s, primarily due to the potential impact of the wastage provision of the 2021 infrastructure bill. When forecasting our license revenue, We anticipate receiving a $5 million milestone payment from EQRX in the first half of 2023 due upon dosing of their first patient in their pivotal trial for Lerocyclib. Regarding expense guidance, we've completed a reduction in force of approximately 30% and have also reduced anticipated spend throughout the organization. We currently expect our 2023 operating expenses to be 20 to 30% lower than that of 2022. While we won't see an impact in the first quarter due to severance and costs associated with reading out and winding down Preserve 1, we'll start to experience these savings in the second quarter, with most of it occurring in the back half of the year. With these adjustments to OPEX, the top-line guidance provided, and other assumptions around partner revenue, we anticipate a year-end cash equivalence and marketable securities balance of approximately $70 to $80 million. With that, I'll turn the call back over to Jack for some closing comments. Jack?
spk00: Thank you, Jen, Raj, Andrew, and Will. As always, I also want to thank people living with cancer for your inspiration. You drive us toward our goals every day. Now, as I mentioned at the start, we have three core goals for the remainder of the year. First, we remain confident in the potential of COSELLA in lung cancer. And as you heard from Andrew, we made good progress since the end of the third quarter. including returning to vile volume growth in the fourth quarter of 2022, with month-over-month growth throughout the fourth quarter, January being our highest vile volume month since launch, and volume strength has continued through February. We've added nearly 100 new accounts in the fourth quarter, including eight new top 100 organizations, with two more added since the start of Q1, to continue to build that broad platform for future growth. Given our progress, we have provided formal guidance this morning of between $50 and $60 million in net co-sellable revenue in 2023. Second, clinical trial execution. Our initial Phase II readouts over the past several months have been compelling, in particular from the ADC and MOA trials. As you heard from Raj, we expect to present more comprehensive data from both of those in the second quarter, followed by additional data from the bladder cancer trial mid-year. We believe that positive data from any of them should be important value drivers for us, as they will clarify the next indications and combinations we will pursue. And given that the number of events occurring more slowly than anticipated, the interim OS analysis for the pivotal TMBC trial is now expected in the first half of 2024. And third, capital preservation. Although it's difficult to make these decisions, we are, as of yesterday, smaller than we were on our February 13th call, and we are making prudent reductions to our spend to extend our cash runway throughout each of our clinical readouts. Finally, as you saw in this morning's press release, this will be Jen's last call with us as Chief Financial Officer. As part of our succession planning, Jen has resigned from G1, effective on the 15th of this month, but will remain on as a senior advisor for one year. On behalf of the entire executive team, I want to express my gratitude to her for everything she brought to the CFO role and for her dedication to the cancer patients we seek to treat. At the same time, I'm pleased to announce that our controller, John Umstead, will be appointed to the role of CFO. John has been with G1 since 2018 after five years with PricewaterhouseCoopers before that, and we look forward to introducing him on our next call. Thank you for your time this morning. We will speak again in this format on the first quarter of 2023 call, and we'll have a variety of opportunities to communicate the upcoming data from our Phase II trials throughout the year. With that, I'll close the call and turn it over to Q&A. Operator, would you please remind our listeners how to ask a question?
spk06: Certainly. As a reminder, to ask a question, please press star 1-1 on your telephone and wait for your name to be announced. To withdraw your question, please press star 1-1 again. Please stand by while we compile the Q&A roster. And our first question comes from the line of Gil Blum with Needham & Company. Gil Blum Good morning, and thanks for taking our question.
spk09: Just to make sure I got this sort of correct, so the pivotal breast cancer study will be reading its interim next year due to a slow accumulation of events or difficulty in enrolling.
spk04: Hey, Gail, I can address that one. No, it's a slower accumulation of events. The trial is fully enrolled with 187 patients.
spk09: Okay. That's important to understand. The other question that I have is we discussed some postmortem analysis on the PreserveOne study. Any potential timeline guidance on when we might be able to see that data?
spk04: Yeah, those are active analyses now. And so I'd say over the upcoming months, we should have more information. Our leading hypothesis, as I mentioned, is really 5FU. And we're looking at how patients did both on the adduction part of the study and the maintenance part of the study. And we have some thoughts on what might have happened. But we need to do some more analyses to sort of gain more firm footing on that hypothesis.
spk09: On the commercial end, it appears that you've been broadening the number of accounts in order to increase the flow of patients given relatively fast turnover because of the way the treatment is provided. How are you planning to drive more growth here? Is there more white space to be had?
spk05: Thanks, Gail. Yes. So many of those new accounts, and we talked about roughly 100 new accounts coming on board in Q4 and extending it around one per day going into Q1. Many of those accounts are actually affiliated with a large parent organization, one of the top 100 or beyond the top 100. So really it becomes a measure of depth when a new account comes on board in the vast majority of cases. And that can be driven by standardization in the EMR, which we've seen can very quickly drive COSELLA uptake when the EMR has COSELLA as a standard option for patients coming in receiving chemotherapy. Or in some cases, it can be driven by internal marketing from the large organization that has discovered that COSELLA is aligned with their corporate interests and they want all of their related attention to use the product. Or it can be related to, in some cases, our large organization community contracts community oncology contracts where the parent organization determines that COSELLA is on contract system with their organizational goals, and they cascade the use of COSELLA through the organization, and then new accounts become aware of it as the parent organization cascades that information.
spk09: All right. Thank you for taking our questions, and good luck.
spk06: Thank you, Joe. Thank you. And our next question comes from the line of Joseph Thum with Cowan.
spk08: Hi, there. Good morning. Thank you for taking our questions. Maybe the first one to something in combination with Tridelvi. What sort of PFS improvement are you looking for when we see that data update? And is the correct comp sort of five months here? And then when you think about the decision to go forward and maybe advance this to next steps, would you be waiting for overall survival? And could we see those data maybe closer to the end of this year? Thanks.
spk04: Hey, Joe. Yeah, the comp, as you said, in this step, it's around that five-month mark for PFS. But we'll be looking at, you know, all of the data, so response rate, duration of response. And as I mentioned, also the tumor PD-L1 status, so it'll be a totality of the data that we'll see. And those will be the key drivers, you know, for the next step. Yeah, we wouldn't wait for overall survival. It would really be what these early indicators of efficacy show.
spk08: Great, and then maybe just a commercial question. What's sort of the average length of time a patient is on Casella in the real world? And as some of these new accounts are coming on in the fourth quarter, are you seeing them being used in different patients so that that sort of overall usage timeline could potentially expand in the years to come? How are you thinking about average use?
spk05: Yeah, thanks. So as you know, in the first line setting, you would expect around four cycles on 21-day cycles. And on average, we see probably around about 3.3 to 3.5 cycles. Sometimes that's due to patients starting in the second cycle or the third cycle. Sometimes it's also due to patients being initiated in an inpatient setting where they'll only receive one cycle and then being discharged to the community where they'll receive the subsequent cycles. And of course, our analysis doesn't always pick up on that. So we're... When people use Costella in that setting, they do tend to use it for every cycle.
spk08: Great. Thank you very much.
spk06: Thanks, Joel. Thank you. And our next question comes from the line of Dane Leone with Raymond James. Hi.
spk07: Thanks for taking the question. Congratulations on the progress. So, your commentary around the start of the year for Casella uptake was obviously highly encouraging with the explicit financial guidance. But can you just take us through what you think has catalyzed the expanded use and adoption of Casella? Obviously, you know, for the prior three quarters in 2022, sales were relatively flat, but it seems like you've been able to invigorate some growth there. Anything you can elucidate in terms of what's driving that I think would be super helpful. Thank you.
spk05: Yeah, thanks. So obviously we had great success in Q2, and we saw 60% volume growth within the quarter of Q2. Much of that was driven by the addition of new accounts and new patients. We were not as successful in driving new accounts and new patients in Q3. We only added 70 in Q3 compared with over 100 in Q2. Q4, we were back to strength, adding new accounts in Q4 and new patients in Q4. And that's really been the driver because as those new accounts come on board, some of that new account business then goes into Q1 of 2023. So it gave us a much better exit path into the next quarter. You know, the reasons for that, so we've focused very much on pull-through in the community and on improving our ability to execute within community clinics. We've discovered that the reasons for that are improved access, the opportunity for standardized EMRs that I referred to earlier, obviously the success so far of our contracts and the potential for more of that, and the economic value proposition that Cosell has had ever since launch, which is very appealing in the community setting. And some of those community organizations as they come on board, they can range from five, six, ten individual accounts to sometimes 80 to 100 individual accounts within one organization. And as you see trial and then the physicians prescribing the product seeing the benefits of the product, wanting to communicate that through peer-to-peer, you can see a very rapid option throughout the rest of a community oncology network. So that's definitely been our sweet spot for execution in Q4. We've doubled down there and we've seen that success continue into Q1.
spk07: Great, thank you. And maybe another follow-up question for me. Can you just contextualize what the scale and scope of the data from the phase two study will be in the second quarter? I guess number of patients and median duration of follow-up would be super helpful for people to set expectations. Thank you.
spk04: Yeah. Hey, Dane. So, we'll, you know, this is Raj. We'll provide, of course, updated safety data and you know, data on all the patients, as I said, we'll be completing the enrollment. We expect approximately 30 patients worth of data at the time. You know, enrollment's been going on for longer than a year, about a year and two or three months. So, you know, I couldn't tell you what the median duration of follow-up would be at the time of the presentation, but obviously it would be long enough for us to make a call on these preliminary PFS. And I think the other point is, you know, since tumor PD-L1 status is an important consideration and we're also evaluating the immune hypothesis here for trial, that will be another important aspect of the mechanism that we will be also currently evaluating and then presenting.
spk07: Thank you. And sorry, one last one for me. The question I think we're getting in relates to some of the earlier questions, but does Preserve 2 actually have a futility analysis on OS designed into the study that could be evaluated before the readout in the first half of 24? I think people are asking that question within the context of understanding what the actual hazard ratio needs to be on OS. as an endpoint and whether it would be prudent to maybe look at an interim and see if, you know, there could be futility in continuing the study. Thank you.
spk04: Yeah, Dane, we did not include a futility analysis. It was really an interim for improvement and efficacy, and primarily because of the signal we saw from our Phase II study. So... Obviously, the other comment I'd make is the data monitoring committee reviews the data regularly, so if they feel like they need to run a futility analysis, they could, of course, do that on their own as well. Okay, thank you.
spk06: Sure. Thank you. And as a reminder, to ask a question, please press star 11 on your telephone. One moment, please. And our next question comes from the line of Priyanka Grover with J.P. Morgan.
spk01: Hi, everyone. This is Priyanka on for Anupam Rama. We just had a quick question. What exactly or could you provide some color was driving the delta between the 2023 guidance of 50 to 60 million on metrics? Is it just penetration or is there some seasonality like in the third quarter in SCLC? Thank you.
spk05: Yeah, so what's driving it is the rate of increase that we have seen in our success mainly in these community clinics and the rate of continued adoption in new accounts and our estimate of how that will extend through the year based on what we've learned so far about the Costella pattern of adoption. Again, I would say that, you know, the single biggest thing that will drive our success in this market is when we move quickly from trial to adoption and one, the first patient to multiple patients and then multiple accounts within an organization with multiple patients. We've seen great success over the last few months with that strategy. We're doubling down on that strategy going into this year and our forecast is really based on that dynamic. You know, and I think it's important to remember this is a Several hundred million dollar markets, $700 million market, we are scratching the surface of the potential here. There is plenty of room for us to grow and achieve these targets.
spk01: Understood. Thank you so much.
spk06: Thank you. And I'm showing no further questions. So with that, I'll hand the call back over to CEO Jack Bailey for any closing remarks.
spk00: Great. Thank you, Operator. As always, we look forward to keeping everybody updated on our progress. But for now, that concludes this call. Thank you for joining us today. We'll look forward to being in touch.
spk06: Ladies and gentlemen, this does conclude today's program. You may now disconnect.
Disclaimer